View Author
patient cancer study chemotherapy survival surgery treatment tumor group paclitaxel response stage carcinoma debulking disease debulking surgery analysis oncol month cycle table trial cisplatin result pharmacokinetic topotecan phase toxicity level course grade women docetaxel carboplatin number parameter interval administration report r 101933 gynecol tumour oncology university cytoreduction neoadjuvant chemotherapy epithelial serum plasma percent interval debulking surgery cpt -11 schedule cytoreductive surgery infusion hospital netherland adjuvant chemotherapy platinum b.i.d death preoperative concentration therapy effect range neoadjuvant paclitaxel /carboplatin model van der burg pathology platelet sample -11 center resistance albumin value signi /carboplatin
10 Most Recent Publications
|
Long-term results of weekly paclitaxel carboplatin induction therapy: An effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer
(Article)
Burg, M.E.L. van der Vergote, I. Onstenk, W. Boere, I.A. Leunen, K. Montfort, C.A.G.M. van Doorn, H.C. van |
2013-04-01
|
|
Genomic aberrations relate early and advanced stage ovarian cancer
(Article)
Zaal, A. Peyrot, W.J. Meijer, G.A. Piek, J.M.J. Timmers, P.J. Vergote, I. Verheijen, R.H.M. Ylstra, B. Zweemer, R.P. Berns, P.M.J.J. Burg, M.E.L. van der Veerbeek, J.H.W. Trimbos, J.B. Cadron, I. Diest, P.J. van Wieringen, W.N. Krijgsman, O. |
2012-06-01
|
|
Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients
(Article)
Vencken, P.M.L.H. Kriege, M. Seynaeve, C.M. Hoogwerf, D. Beugelink, S. Burg, M.E.L. van der Hooning, M. Berns, P.M.J.J. Jager, A. Collée, J.M. Burger, C.W. |
2011-06-06
|
|
Early versus delayed treatment of relapsed ovarian cancer
(Article)
Rustin, G.J.S. Burg, M.E.L. van der Griffin, C.L. Qian, W. Swart, A.M. |
2011-01-29
|
|
Early versus delayed treatment of relapsed ovarian cancer
(Article)
Rustin, G.J.S. Burg, M.E.L. van der Griffin, C.L. Qian, W. Swart, A.M. |
2011-01-29
|
|
Quality of pathology reports for advanced ovarian cancer: Are we missing essential information?: An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial
(Article)
Verleye, L. Ottevanger, P.B. Seoane, J.M. Velden, J. van der Lotocki, R. Graaf, W.T.A. van der Penninckx, B. Coens, C. Stuart, G.C.E. Vergote, I. Kristensen, G.B. Ehlen, T. Johnson, N. Burg, M.E.L. van der Reed, N.S. Verheijen, R.H.M. Gaarenstroom, K.N. Mosgaard, B. |
2011-01-01
|
|
B-cell maturation and antibody responses in individuals carrying a mutated CD19 allele
(Article)
Artac, H. Reisli, I. Burg, M.E.L. van der Zelm, M.C. van Kara, R. Pico-Knijnenburg, I. Adin-Çinar, S. Pekcan, S. Jol-van der Zijde, C.M. Tol, M.J.D. van Bakker-Jonges, L.E. Dongen, J.J.M. van |
2010-10-01
|
|
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
(Article)
Vergote, I. Tropé, C.G. Kenter, G.G. Casado, A. Mendiola, C. Coens, C. Verleye, L. Stuart, G.C.E. Pecorelli, S. Reed, N.S. Amant, F. Kristensen, G.B. Ehlen, T. Johnson, N. Verheijen, R.H.M. Burg, M.E.L. van der Lacave, A.J. Panici, P.B. |
2010-09-02
|
|
Surgical staging and treatment of early ovarian cancer: Long-term analysis from a randomized trial
(Article)
Trimbos, B. Timmers, P.J. Pecorelli, S. Coens, C. Ven, K. Burg, M.E.L. van der Casado, A. |
2010-07-01
|
|
Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs
(Article)
Helleman, J. Jansen, M.P.H.M. Burger, C.W. Burg, M.E.L. van der Berns, P.M.J.J. |
2010-01-01
|
